Valuation: Merrimack Pharmaceuticals Inc

Market Cap 224M 196M 181M 166M 314M 21.54B 321M 2.16B 850M 10.55B 840M 822M 36.37B P/E 2022
-100x
P/E 2023 -162x
Enterprise Value 205M 179M 166M 152M 287M 19.72B 294M 1.98B 778M 9.66B 769M 752M 33.3B EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
98.81%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer 74 28/06/2019
Investor Relations Contact - -
Director TitleAgeSince
Chairman 74 01/01/2005
Change 5-day change 1-year change 3-year change Capi.($)
+8.74%-10.76% - - 224M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+588.97% 39.58B
-1.70%+4.46%+5.93%+61.54% 34.69B
-2.01%-0.76%+28.41%-8.52% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+116.45% 15.36B
+1.12%+1.91%+14.54%+15.44% 14.05B
0.00%+1.36%+18.43%-31.23% 13.02B
Average +0.92%+0.03%+65.98%+97.52% 27.07B
Weighted average by Cap. -0.05%-0.18%+79.44%+122.39%

Financials

2022 2023
Net sales - -
Net income -1.54M -1.35M -1.25M -1.15M -2.16M -149M -2.21M -14.93M -5.86M -72.8M -5.8M -5.67M -251M -1.18M -1.03M -955K -879K -1.66M -114M -1.69M -11.42M -4.48M -55.68M -4.43M -4.34M -192M
Net Debt -19.44M -17.02M -15.72M -14.46M -27.25M -1.87B -27.86M -188M -73.81M -917M -73M -71.39M -3.16B -18.88M -16.52M -15.27M -14.04M -26.46M -1.82B -27.06M -183M -71.67M -890M -70.88M -69.32M -3.07B
Logo Merrimack Pharmaceuticals Inc
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Employees
-